Tracy Beth Hogue, the acting director of the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research, has stated that she was dismissed by the agency. Tracy Beth Hogue is expected to leave the FDA on Friday, just days after Commissioner Marty Makary resigned. Hogue announced her departure via the X platform. She is an epidemiologist and sports medicine physician who had raised questions about COVID-19 vaccines during the pandemic. She also led efforts to reform the U.S. childhood vaccination schedule, reducing the recommended number of shots from 17 to 11 in January of this year. Hogue's departure comes as the health department undergoes broader personnel changes. In recent months, the White House has increased its oversight of the department. The White House appointed Chris Klomp as Kennedy's deputy, after which Klomp assisted in nominating a slate of more traditional candidates for key health department positions, such as the director of the Centers for Disease Control and Prevention (CDC) and the Surgeon General. According to two sources, since Makary resigned on Tuesday, Klomp has been working to remove controversial appointees within the FDA and replace them with more conventional choices.
Comments